Teva Seeks to Block Lilly’s Competing, Unapproved Migraine Drug

Teva Pharmaceuticals International GmbH says an Eli Lilly and Co. yet-to-be-approved migraine drug infringes patents on its own putative migraine product as the Israeli drugmaker seeks to pull out of a tailspin.

Eli Lilly’s galcanezumab biologic infringes Teva’s U.S. Patent Nos. 9,884,907 and 9,884,908, which cover the fremanezumab biologic, Teva said in a lawsuit filed Feb. 6. Both drugs await Food and Drug Administration approval.

Teva said in its suit it has “invested heavily” in its biologic and “the potential benefit to the public is enormous.” More than a billion people deal with migraine headaches worldwide, including 38 million ...